Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors
Loading...
Official URL
Full text at PDC
Publication date
2023
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Geographic coverage
Citation
González-Cofrade L, P. Green J, Cuadrado I, Amesty Á, Oramas-Royo S, David Brough, Estévez-Braun A, Hortelano S, De Las Heras B. Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors. Bioorganic Chemistry 2023;132:106362. https://doi.org/10.1016/j.bioorg.2023.106362.
Abstract
Dysregulated inflammasome activity, particularly of the NLRP3 inflammasome, is associated with the development of several inflammatory diseases. The study of molecules directly targeting NLRP3 is an emerging field in the discovery of new therapeutic compounds for the treatment of inflammatory disorders. Friedelane triterpenes are biologically active phytochemicals having a wide range of activities including anti-inflammatory effects. In this work, we evaluated the potential anti-inflammatory activity of phenolic and quinonemethide nor-triterpenes (1–11) isolated from Maytenus retusa and some semisynthetic derivatives (12–16) through inhibition of the NLRP3 inflammasome in macrophages. Among them, we found that triterpenes 6 and 14 were the most potent, showing markedly reduced caspase-1 activity, IL-1β secretion (IC50 = 1.15 µM and 0.19 µM, respectively), and pyroptosis (IC50 = 2.21 µM and 0.13 µM, respectively). Further characterization confirmed their selective inhibition of NLRP3 inflammasome in both canonical and non-canonical activation pathways with no effects on AIM2 or NLRC4 inflammasome activation.